Use of allogeneic stem cell transplantation for moderate-severe Glanzmann thrombasthenia

Amy Walz*, Alicia Lenzen, Brian Curtis, Jason Canner, Jennifer Schneiderman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Glanzmann thrombasthenia (GT) is a rare, autosomal recessive coagulopathy characterized by either qualitative or quantitative abnormalities of the membrane glycoprotein αIIbβ3 complex leading to bleeding tendencies, ranging from purpura to life-threatening hemorrhage. Although patients can be managed with supportive measures including platelet transfusions, complications such as alloimmunization are possible. Allogeneic stem cell transplantation (ASCT) can be indicated in severe cases of GT. We report the case of an eight-month-old girl diagnosed with moderate-severe GT, who was successfully treated with a reduced-intensity, human leukocyte antigen (HLA)-identical ASCT.

Original languageEnglish (US)
Pages (from-to)702-704
Number of pages3
Issue number7
StatePublished - Oct 3 2015


  • Glanzmann thrombasthenia
  • pediatric hematology/oncology
  • platelet disorders
  • stem cell transplant

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Use of allogeneic stem cell transplantation for moderate-severe Glanzmann thrombasthenia'. Together they form a unique fingerprint.

Cite this